drugset
drugset / Trial / NCT04967014

Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers

NCT04967014 ↗

Phase 1 Completed 32 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

A Phase 1 Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers

Timeline

Start
2021-05-06
Primary completion
2021-06-01
Completion
2021-06-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject HIP2101 Unknown 10 mg Oral
Subject RLD2101 Unknown 20 mg —

Indications

No indication recorded.